My Prognosis


C9076

Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Terminated September 30, 2021.

Notice
Short Description
HCPCS Coverage Code
HCPCS Action Code
HCPCS Action Effective Date
HCPCS Code Added Date
HCPCS Termination Date
HCPCS Pricing Indicator Code
HCPCS Multiple Pricing Indicator Code
HCPCS Statute Number
HCPCS Type Of Service Code
HCPCS Anesthesia Base Unit Quantity